
    
      OUTLINE:

      Patients receive gemtuzumab ozogamicin intravenously (IV) on days 1, 4, 7. Treatment
      continues for 35 days in the absence of disease progression or unacceptable toxicity.
      Responders and non-responders, without significant adverse events during the first course,
      may receive a second course of gemtuzumab ozogamicin within 60 days after course 1.

      After completion of study treatment, patients are followed up for 6 months.
    
  